Pharma stocks
-
November 23, 2020, Monday
Pharma shares in focus; Divi's Labs hits new high, Gland Pharma zooms 20%
Dishman Carbogen Amcis, Ipca Lab, SPARC, Caplin Point Laboratories, Dr. Lal PathLabs and Granules India from the S&P BSE ...
-
November 17, 2020, Tuesday
'Banking sector a good long-term bet despite expensive valuation'
The market expects a strong bounce in earnings growth in FY22 with a growth of more than 30 per cent on a YoY basis.
-
November 14, 2020, Saturday
IT, pharma firms emerge Samvat 2076 winners; Infy, Divi's Lab top gainers
On the other hand, PSU stocks and banks have been laggards - with ONGC, Indian Oil, IndusInd Bank, and Coal India delivering the ...
-
November 11, 2020, Wednesday
Divi's Lab, Aurobindo Pharma: Are pharma stocks losing their sheen? Read on
Till Nifty Pharma holds above the 11,180 mark, the bullish bias will prevail, charts suggest.
-
October 29, 2020, Thursday
Tata Motors to Bharat Forge: Stock winners and losers in India from US Vote
Here are some key things to watch in India with respect to the upcoming US vote
-
October 26, 2020, Monday
Divestment of US subsidiary to leave Aurobindo Pharma cash positive
Divestment of the US subsidiary is at good valuations and will help attain net cash positive status
-
October 19, 2020, Monday
Edelweiss's healthcare fund offers benefit of international diversification
Allocation to a thematic offering like the newly-launched healthcare index fund should, however, be limited
-
October 13, 2020, Tuesday
Kopran hits 52-week high after Crisil upgrades rating outlook to 'Positive'
The rating agency reaffirmed its 'CRISIL BBB' rating on long term bank facilities, while short term ratings has been reaffirmed ...
-
October 13, 2020, Tuesday
Pharma stocks gain; Cipla hits record high, Lupin nears 52-week high
In the past month, Cipla and Lupin outperformed the market by gaining 12 per cent each, against 8 per cent rise in Nifty Pharma ...
-
October 11, 2020, Sunday
GSK Pharma's growth challenges to remain in near term as Covid dents sales
Even as overall pharma market was up 5% over the year-ago period, GSK's September sales were down 8%, the firm is banking on ...
